European Medicines Agency Approves OXBRYTA® (voxelotor), First Treatment Approved in the EU to Target the Cause of Sickle Cell Disease

/PRNewswire/ -- Brand Institute is proud to announce its successful partnership with Global Blood Therapeutics (GBT) in naming their EMA-approved therapy,...

Related Keywords

Miami ,Florida ,United States ,Canada ,American ,Scott Piergrossi ,Jamesl Dettore ,Drug Safety Institute ,Brand Institute ,World Health Organization ,Brand Institute Inc ,Drug Safety Institute Team ,American Medical Association ,Prnewswire Brand Institute ,Health Canada ,Global Blood Therapeutics ,Drug Safety ,Safety Institute ,Nc ,